share_log

Cancer-Focused Coeptis Therapeutics Turns To SPAC Deal To Uplist To NASDAQ

Cancer-Focused Coeptis Therapeutics Turns To SPAC Deal To Uplist To NASDAQ

以癌症為中心的 Coeptis 治療藥物轉向 SPAC 交易升至納斯達克
Benzinga Real-time News ·  2022/04/20 15:50
  • Coeptis Therapeutics Inc (OTC:COEP) has agreed to a $175 million merger deal with Bull Horn Holdings Corporation (NASDAQ:BHSE), a special purpose acquisition company.
  • Upon completing the deal, Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings Inc. and is expected to be listed on Nasdaq under the ticker symbol COEP.
  • With this transaction, expected to be completed in the third quarter, the shareholders of Coeptis will receive equity in Bull Horn valued at $175 million.
  • Related: Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform.
  • The merger is anticipated to push Coeptis' efforts to boost its cell therapy platforms to treat cancer.
  • Coeptis is a developer of cell therapy platforms for cancer. Its product portfolio is highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is co-developing with VyGen-Bio Inc. 
  • CD38-GEAR-NK is a natural killer (NK) cell-based investigational therapeutic that enables combination therapy with anti-CD38 monoclonal antibodies (mAbs).
  • Coeptis' current President and CEO, David Mehalick, will lead the combined company as President & CEO. The current Chief Financial Officer of Bull Horn, Chris Calise, will join the post-closing Board of Directors.
  • Price Action: COEP shares are down 26.6% at $4.11 during the market session on the last check Wednesday.
  • 科普蒂斯治療公司(OTC: COEP) 已同意達成 1.75 億美元的合併協議牛角控股有限公司(納斯達克:BHSE), 一家特殊目的收購公司.
  • 完成交易後，Bull Horn 將被更名並以 Coeptis 治療控股公司的身份運營，並預計將以股票代碼 COEP 在納斯達克上市。
  • 通過這項交易，預計將在第三季度完成，Coeptis 的股東將獲得價值 1.75 億美元的公牛角股權。
  • 相關： 科普炎治療藥物打算收購斯泰拉的 TLR5 激動劑平台。
  • 這次合併預計將推動 Coeptis 努力推動其細胞治療平台以治療癌症。
  • Coeptis 是癌症細胞治療平台的開發者。其產品組合以細胞治療技術（CD38-GEAR-NK）和針對 CD38 相關癌症的體外診斷（CD38-診斷）突出顯示，Coeptis 正在與 Coeptis 共同開發維根生物科技有限公司。
  • CD38-GEAR-NK 是一種基於細胞的自然殺手（NK）研究治療，可與抗 CD38 單克隆抗體（MAs）進行聯合治療。
  • Coeptis 現任總裁兼首席執行官 David Mehalick 將帶領合併後的公司擔任總裁兼首席執行官。牛角現任首席財務官克里斯·卡利塞（Chris Calise）將加入閉幕後的董事會。
  • 價格行動：在上次檢查週三的市場時段中，COEP 股價下跌 26.6%，為 4.11 美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論